Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/fibroblast-activation-protein-targeted-pet-imaging-of-metastatic-WNK6uemop4
References (9)
-
A Paschalis, B Sheehan, R Riisnaes (2019)
Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer, 76
-
Y Sanli, S Kuyumcu, O Sanli (2017)
Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer, 31
-
FL Giesel, C Kratochwil, T Lindner (2019)
(68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers, 60
-
T Lindner, A Loktev, A Altmann (2018)
Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein, 59
-
SP Thang, J Violet, S Sandhu (2019)
Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for (177)Lu-labelled PSMA radioligand therapy, 2
-
C Kratochwil, WP Fendler, M Eiber (2019)
EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT), 46
-
R Chen, Y Wang, Y Shi (2021)
Diagnostic value of 18F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative 68Ga-PSMA PET/CT -
K Michalski, J Ruf, C Goetz (2021)
Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy, 48
-
C Kratochwil, P Flechsig, T Lindner (2019)
(68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer, 60
- Publisher
- Wolters Kluwer Health
- Copyright
- Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
- ISSN
- 0363-9762
- eISSN
- 1536-0229
- DOI
- 10.1097/rlu.0000000000003837
- Publisher site
- See Article on Publisher Site
Abstract
Abstract Herein we present 2 mCRPC (metastatic castration-resistant prostate cancer) patients who underwent 68Ga-PSMA PET/CT for PSMA-targeted radioligand therapy eligibility. Prior studies have noted aggressive clinical behavior and poor prognosis associated with discordant FDG positivity and low PSMA expression. Accordingly, the patients also underwent 18F-FDG PET/CT, which revealed intratumoral heterogeneity. Therefore, an additional PET/CT targeting fibroblast activation proteins (FAPs) using 68Ga-FAPI-04 was performed to assess the potential for an FAP-targeted therapy. This report highlights the theranostic potential of FAP imaging in mCRPC, particularly in patients with heterogeneous tumor phenotypes.
Journal
Clinical Nuclear Medicine – Wolters Kluwer Health
Published: Jan 13, 2022